Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Country / region: Canada Clear all

391 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20014
20026
20037
20048
200512
200612
200717
200816
200922
201022
201125
201220
201323
201417
201520
201624
201721
201811
201913
20208
202111
202217
202318
202412
202516
20266

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed283
Unknown status40
Terminated26
Recruiting25
Active, not recruiting8
Not yet recruiting4
Withdrawn3
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca41
Boehringer Ingelheim40
Laval University32
GlaxoSmithKline31
University of Alberta16
University of British Columbia16
Novartis Pharmaceuticals15
West Park Healthcare Centre15
McGill University Health Centre/Research Institute of the McGill University Health Centre14
Queen's University12

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive391
Dyspnea32
Heart Failure26
Asthma25
Emphysema25
Bronchitis, Chronic22
Diabetes Mellitus15
Hypertension12
Lung Diseases12
Lung Diseases, Interstitial12

Trials

Showing 76 to 100 of 391. Each trial links to its page on Pharma Observatory.

291 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.